2010年03月23日

アステラス製薬、OSI定時総会への推薦取締役候補者を2人変更

【カテゴリー】：経営（海外） 【関連企業・団体】：アステラス製薬

ステラス製薬は23日、OSI Pharmaceuticals, Inc.（本社：米国ニューヨーク州メルビル）の2010年定時株主総会に選任提案を行う予定の取締役候補者のうち2名を変更すると発表した。 3月17日に発表した推薦候補10氏のうち、Jack Kaye 氏と Heidi L. Steiger氏の2名に代えて、新たに John D. Gilly氏と Margaret T. Monaco氏の2名を取締役候補者に推薦することを同社に通知した。 ＜新たに推薦する取締役候補者（2名）＞ ・Dr. Gilly currently serves as an Associate Director in the Biopharmaceutical Development Program with SAIC-Frederick, Inc., at NCI-Frederick, Inc., a federally funded research and development center focused on oncology. Prior to joining SAIC-Frederick, Inc., he served as a director and Chief Operating Officer of Premier Research Group, plc, a U.K.-based publicly traded research organization that provides clinical trail services to biopharmaceutical and medical device companies, from 2006 through 2007, and as president of Premier Research Group’s U.S. operations from 2002 through 2006. ・Margaret T. Monaco is the Principal of Probus Advisors, a financial and strategic consulting firm. She currently sits on the board and is a member of the audit committee of Barnes & Nobles, Inc. (NYSE). Ms. Monaco has also served as an independent director and member of the audit committee of W.P. Stewart & Co. Growth Fund, Inc. (WPSGX) and is a former Chief Operating Officer of Merrill Lynch Ventures, LLC / KECALP Inc. ＜以前からの推薦取締役候補者（8名）＞ ・Martin Edelshain served as an executive for Gen-Probe Inc., a molecular diagnostics company, and its former parent, Chugai Pharmaceutical Co., Ltd, from 1995 to 2008. Mr. Edelshain was instrumental in forming the 2002 strategic alliance between Chugai Pharma and Roche. ・Cono R. Fusco spent 34 years as a partner at Grant Thornton LLP, one of the top global accounting firms. His career spanned virtually all aspects of the firm’s operations, including client service, office, regional and national managing partner positions, National Leadership Team, and Partnership Board member. ・Michael A. Griffith was the founder and CEO of Aptuit Inc., a leading global pharmaceutical contract research, development and manufacturing company until 2008. In 2002, he was appointed Chairman of the Executive Committee of Centrue Financial Corporation. ・Jill Kanin-Lovers has served on the Board of Alpharma Inc., a specialty pharmaceutical firm, First Advantage, a leading risk mitigation and business solutions provider and Heidrick & Struggles International Inc. ・Douglas E. Linton has served on the board of Bradley Pharmaceuticals and as vice president of Cardinal Health Inc. He was an Executive Advisor at Campbell Alliance Group, a management consultant that specializes in pharmaceuticals and biotech until 2009. ・Timothy P. Lynch is a General Partner of Stonepine Capital, L.P., a partnership focused on investing in public, small-cap biotech and pharmaceutical companies. He serves on the strategic advisory board of the Cowen Healthcare Royalty Fund and on the boards of Allos Therapeutics, Inc., Insite Vision Inc., and Nabi Biopharmaceuticals and is the former Chief Financial Officer of Tercica, Inc. ・Jonathan R. Macey serves as the Sam Harris Professor of Corporate Law, Corporate Finance and Securities Law at Yale University and is a Professor at the Yale School of Management. He is a member of the National Adjudicatory Council of the Financial Industry Regulatory Association (“FINRA”) and until 2009 served as a director on the board of WCI Communities, Inc. ・Joseph L. Turner currently sits on the boards of QLT Inc., ApopLogic Pharmaceuticals, Inc., Kythera Biopharmaceuticals, Inc., Sequel Pharmaceuticals, Inc. and Swarthmore College. He has served as Chief Financial Officer of Myogen, Inc. and Centaur Pharmaceuticals. ニュースリリース参照 http://www.chem-t.com/fax/images/tmp_file1_1269303254.pdf